Amanda K. Ombrello
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Amanda K. Ombrello has a total of 459 co-authors. Here are the top co-authors by number of shared publications:
Ivona Aksentijevich
National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland
11 shared publicationsQing Zhou
Life Sciences Institute, Zhejiang University, Zhejiang, China
10 shared publicationsPatrycja Hoffmann
8 shared publications- Natalie Deuitch
NHGRI, NIH, Bethesda, Maryland, United States
7 shared publications Anne Jones
Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
6 shared publications- Daniel L. Kastner
National Human Genome Research Institute, National Institutes of Health, Bethesda, USA
6 shared publications
Latest Publications
- Top Cited Papers
- 1 May 2023
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 6 (5) , e2315894
Evaluation and Management of Deficiency of Adenosine Deaminase 2
Deficiency of adenosine deaminase 2 (DADA2) is a monogenic autoinflammatory disease characterized by systemic vasculitis, early-onset stroke, bone marrow failure, and/or immunodeficiency.1,2 DADA2 is caused by biallelic pathogenic variants in the ADA2 gene (formerly known as CECR1) on chromosome 22q11.3 This condition was first described in 2014 and more than 400 cases have been published to date.4,5 While affected individuals were mostly young children in the early case series, adult-onset cases of DADA2 are increasingly recognized.6,7 Based on population genetics, the aggregate carrier frequency of deleterious ADA2 variants is approximately 1 in 236 individuals, which translates into an estimated disease prevalence of 1 case per 222 000 individuals.8 This estimate makes DADA2 a rare disease according to the US Food and Drug Administration.9 However, such prevalence also establishes DADA2 as a more common monogenic autoinflammatory diseases with an estimated 35 000 affected individuals worldwide.8
- 1 May 2023
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 6 (5) , e2315894
Top Cited PapersEvaluation and Management of Deficiency of Adenosine Deaminase 2
Deficiency of adenosine deaminase 2 (DADA2) is a monogenic autoinflammatory disease characterized by systemic vasculitis, early-onset stroke, bone marrow failure, and/or immunodeficiency.1,2 DADA2 is caused by biallelic pathogenic variants in the ADA2 gene (formerly known as CECR1) on chromosome 22q11.3 This condition was first described in 2014 and more than 400 cases have been published to date.4,5 While affected individuals were mostly young children in the early case series, adult-onset cases of DADA2 are increasingly recognized.6,7 Based on population genetics, the aggregate carrier frequency of deleterious ADA2 variants is approximately 1 in 236 individuals, which translates into an estimated disease prevalence of 1 case per 222 000 individuals.8 This estimate makes DADA2 a rare disease according to the US Food and Drug Administration.9 However, such prevalence also establishes DADA2 as a more common monogenic autoinflammatory diseases with an estimated 35 000 affected individuals worldwide.8
- 9 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S276-S277
Next generation sequencing panel screening of 320 patients with clinically unclassified systemic autoinflammatory diseases
- 9 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S276-S277
Next generation sequencing panel screening of 320 patients with clinically unclassified systemic autoinflammatory diseases
- 5 November 2020
- Published by Springer Nature
- p. 251-257
DADA2
- 1 October 2020
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 130 (10) , 5425-5443
Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients
Late-onset inflammatory toxicities resembling hemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS) occur after chimeric antigen receptor T cell (CAR T cell) infusion and represent a therapeutic challenge. Given the established link between perforin deficiency and primary HLH, we investigated the role of perforin in anti-CD19 CAR T cell efficacy and HLH-like toxicities in a syngeneic murine model. Perforin contributed to both CD8+ and CD4+ CAR T cell cytotoxicity but was not required for in vitro or in vivo leukemia clearance. Upon CAR-mediated in vitro activation, perforin-deficient CAR T cells produced higher amounts of proinflammatory cytokines compared with WT CAR T cells. Following in vivo clearance of leukemia, perforin-deficient CAR T cells reexpanded, resulting in splenomegaly with disruption of normal splenic architecture and the presence of hemophagocytes, which are findings reminiscent of HLH. Notably, a substantial fraction of patients who received anti-CD22 CAR T cells also experienced biphasic inflammation, with the second phase occurring after the resolution of cytokine release syndrome, resembling clinical manifestations of HLH. Elevated inflammatory cytokines such as IL-1β and IL-18 and concurrent late CAR T cell expansion characterized the HLH-like syndromes occurring in the murine model and in humans. Thus, a murine model of perforin-deficient CAR T cells recapitulated late-onset inflammatory toxicities occurring in human CAR T cell recipients, providing therapeutically relevant mechanistic insights.
- 1 October 2020
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 130 (10) , 5425-5443
Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients
Late-onset inflammatory toxicities resembling hemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS) occur after chimeric antigen receptor T cell (CAR T cell) infusion and represent a therapeutic challenge. Given the established link between perforin deficiency and primary HLH, we investigated the role of perforin in anti-CD19 CAR T cell efficacy and HLH-like toxicities in a syngeneic murine model. Perforin contributed to both CD8+ and CD4+ CAR T cell cytotoxicity but was not required for in vitro or in vivo leukemia clearance. Upon CAR-mediated in vitro activation, perforin-deficient CAR T cells produced higher amounts of proinflammatory cytokines compared with WT CAR T cells. Following in vivo clearance of leukemia, perforin-deficient CAR T cells reexpanded, resulting in splenomegaly with disruption of normal splenic architecture and the presence of hemophagocytes, which are findings reminiscent of HLH. Notably, a substantial fraction of patients who received anti-CD22 CAR T cells also experienced biphasic inflammation, with the second phase occurring after the resolution of cytokine release syndrome, resembling clinical manifestations of HLH. Elevated inflammatory cytokines such as IL-1β and IL-18 and concurrent late CAR T cell expansion characterized the HLH-like syndromes occurring in the murine model and in humans. Thus, a murine model of perforin-deficient CAR T cells recapitulated late-onset inflammatory toxicities occurring in human CAR T cell recipients, providing therapeutically relevant mechanistic insights.
- 11 December 2019
- Published by Springer Nature in Nature
- Vol. 577 (7788) , 103-108
Mutations that prevent caspase cleavage of RIPK1 cause autoinflammatory disease
RIPK1 is a key regulator of innate immune signalling pathways. To ensure an optimal inflammatory response, RIPK1 is regulated post-translationally by well-characterized ubiquitylation and phosphorylation events, as well as by caspase-8-mediated cleavage1,2,3,4,5,6,7. The physiological relevance of this cleavage event remains unclear, although it is thought to inhibit activation of RIPK3 and necroptosis8. Here we show that the heterozygous missense mutations D324N, D324H and D324Y prevent caspase cleavage of RIPK1 in humans and result in an early-onset periodic fever syndrome and severe intermittent lymphadenopathy—a condition we term ‘cleavage-resistant RIPK1-induced autoinflammatory syndrome’. To define the mechanism for this disease, we generated a cleavage-resistant Ripk1D325A mutant mouse strain. Whereas Ripk1−/− mice died postnatally from systemic inflammation, Ripk1D325A/D325A mice died during embryogenesis. Embryonic lethality was completely prevented by the combined loss of Casp8 and Ripk3, but not by loss of Ripk3 or Mlkl alone. Loss of RIPK1 kinase activity also prevented Ripk1D325A/D325A embryonic lethality, although the mice died before weaning from multi-organ inflammation in a RIPK3-dependent manner. Consistently, Ripk1D325A/D325A and Ripk1D325A/+ cells were hypersensitive to RIPK3-dependent TNF-induced apoptosis and necroptosis. Heterozygous Ripk1D325A/+ mice were viable and grossly normal, but were hyper-responsive to inflammatory stimuli in vivo. Our results demonstrate the importance of caspase-mediated RIPK1 cleavage during embryonic development and show that caspase cleavage of RIPK1 not only inhibits necroptosis but also maintains inflammatory homeostasis throughout life.
- 11 December 2019
- Published by Springer Nature in Nature
- Vol. 577 (7788) , 103-108
Mutations that prevent caspase cleavage of RIPK1 cause autoinflammatory disease
RIPK1 is a key regulator of innate immune signalling pathways. To ensure an optimal inflammatory response, RIPK1 is regulated post-translationally by well-characterized ubiquitylation and phosphorylation events, as well as by caspase-8-mediated cleavage1,2,3,4,5,6,7. The physiological relevance of this cleavage event remains unclear, although it is thought to inhibit activation of RIPK3 and necroptosis8. Here we show that the heterozygous missense mutations D324N, D324H and D324Y prevent caspase cleavage of RIPK1 in humans and result in an early-onset periodic fever syndrome and severe intermittent lymphadenopathy—a condition we term ‘cleavage-resistant RIPK1-induced autoinflammatory syndrome’. To define the mechanism for this disease, we generated a cleavage-resistant Ripk1D325A mutant mouse strain. Whereas Ripk1−/− mice died postnatally from systemic inflammation, Ripk1D325A/D325A mice died during embryogenesis. Embryonic lethality was completely prevented by the combined loss of Casp8 and Ripk3, but not by loss of Ripk3 or Mlkl alone. Loss of RIPK1 kinase activity also prevented Ripk1D325A/D325A embryonic lethality, although the mice died before weaning from multi-organ inflammation in a RIPK3-dependent manner. Consistently, Ripk1D325A/D325A and Ripk1D325A/+ cells were hypersensitive to RIPK3-dependent TNF-induced apoptosis and necroptosis. Heterozygous Ripk1D325A/+ mice were viable and grossly normal, but were hyper-responsive to inflammatory stimuli in vivo. Our results demonstrate the importance of caspase-mediated RIPK1 cleavage during embryonic development and show that caspase cleavage of RIPK1 not only inhibits necroptosis but also maintains inflammatory homeostasis throughout life.
- 25 November 2019
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 79 (3) , 429-431
Type I interferon signature predicts response to JAK inhibition in haploinsufficiency of A20
- 25 November 2019
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 79 (3) , 429-431
Type I interferon signature predicts response to JAK inhibition in haploinsufficiency of A20
- Open Access
- 25 July 2019
- Published by American Society of Hematology in Blood
- Vol. 134 (4) , 395-406
Deficiency of adenosine deaminase 2 triggers adenosine-mediated NETosis and TNF production in patients with DADA2
Reduction of adenosine deaminase 2 (ADA2) activity due to autosomal-recessive loss-of-function mutations in the ADA2 gene (previously known as CECR1) results in a systemic vasculitis known as deficiency of ADA2 (DADA2). Neutrophils and a subset of neutrophils known as low-density granulocytes (LDGs) have been implicated in the pathogenesis of vasculitis, at least in part, through the formation of neutrophil extracellular traps (NETs). The study objective was to determine whether neutrophils and NETs play a pathogenic role in DADA2. In vivo evidence demonstrated NETs and macrophages in affected gastrointestinal tissue from patients with DADA2. An abundance of circulating LDGs prone to spontaneous NET formation was observed during active disease in DADA2 and were significantly reduced after remission induction by anti–tumor necrosis factor (TNF) therapy. Increased circulating LDGs were identified in unaffected family members with monoallelic ADA2 mutations. Adenosine triggered NET formation, particularly in neutrophils from female patients, by engaging A1 and A3 adenosine receptors (ARs) and through reactive oxygen species– and peptidylarginine deiminase–dependent pathways. Adenosine-induced NET formation was inhibited by recombinant ADA2, A1/A3 AR antagonists, or by an A2A agonist. M1 macrophages incubated with NETs derived from patients with DADA2 released significantly greater amounts of TNF-α. Treatment with an A2AAR agonist decreased nuclear translocation of NF-κB and subsequent production of inflammatory cytokines in DADA2 monocyte-derived macrophages. These results suggest that neutrophils may play a pathogenic role in DADA2. Modulation of adenosine-mediated NET formation may contribute a novel and directed therapeutic approach in the treatment of DADA2 and potentially other inflammatory diseases.
- 25 July 2019
- Published by American Society of Hematology in Blood
- Vol. 134 (4) , 395-406
Open AccessDeficiency of adenosine deaminase 2 triggers adenosine-mediated NETosis and TNF production in patients with DADA2
Reduction of adenosine deaminase 2 (ADA2) activity due to autosomal-recessive loss-of-function mutations in the ADA2 gene (previously known as CECR1) results in a systemic vasculitis known as deficiency of ADA2 (DADA2). Neutrophils and a subset of neutrophils known as low-density granulocytes (LDGs) have been implicated in the pathogenesis of vasculitis, at least in part, through the formation of neutrophil extracellular traps (NETs). The study objective was to determine whether neutrophils and NETs play a pathogenic role in DADA2. In vivo evidence demonstrated NETs and macrophages in affected gastrointestinal tissue from patients with DADA2. An abundance of circulating LDGs prone to spontaneous NET formation was observed during active disease in DADA2 and were significantly reduced after remission induction by anti–tumor necrosis factor (TNF) therapy. Increased circulating LDGs were identified in unaffected family members with monoallelic ADA2 mutations. Adenosine triggered NET formation, particularly in neutrophils from female patients, by engaging A1 and A3 adenosine receptors (ARs) and through reactive oxygen species– and peptidylarginine deiminase–dependent pathways. Adenosine-induced NET formation was inhibited by recombinant ADA2, A1/A3 AR antagonists, or by an A2A agonist. M1 macrophages incubated with NETs derived from patients with DADA2 released significantly greater amounts of TNF-α. Treatment with an A2AAR agonist decreased nuclear translocation of NF-κB and subsequent production of inflammatory cytokines in DADA2 monocyte-derived macrophages. These results suggest that neutrophils may play a pathogenic role in DADA2. Modulation of adenosine-mediated NET formation may contribute a novel and directed therapeutic approach in the treatment of DADA2 and potentially other inflammatory diseases.
- 18 April 2019
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 380 (16) , 1582-1584
Treatment Strategies for Deficiency of Adenosine Deaminase 2
The manifestations of a deficiency of adenosine deaminase 2, a genetic disease, include early-onset lacunar stroke. In a series of 15 patients with this disorder, treatment with a TNF inhibitor resulted in a reduction from 37 strokes to no strokes during 733 patient-months.
- 18 April 2019
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 380 (16) , 1582-1584
Treatment Strategies for Deficiency of Adenosine Deaminase 2
The manifestations of a deficiency of adenosine deaminase 2, a genetic disease, include early-onset lacunar stroke. In a series of 15 patients with this disorder, treatment with a TNF inhibitor resulted in a reduction from 37 strokes to no strokes during 733 patient-months.